Subjects who need daily oxygen therapy
No chronic (duration >  days) daily use of oral steroids
Refractory/relapsed disease following DNMTi failure; refractory disease defined as either ) failure to achieve an objective response after at least  cycles of DNMTi therapy, or ) failure to achieve an objective response with clear progressive disease on bone marrow biopsy after at least  cycles of DNMTi therapy; relapsed disease is defined as having progressive disease after achieving an objective response after at least  cycles of DNMTi therapy; previous DNMTi therapy may include azacitidine, decitabine, or DNMTi therapy currently in clinical trials (e.g. SGI- [guadecitabine], ASTX or CC-); to be considered DNMTi treatment failure, during each prior treatment cycle, patients must have received minimum dosing of:\r\n* Decitabine  mg/m^ daily x  days, or\r\n* azacitidine  mg/m^ IV/SC daily x  days,\r\n* SGI- (guadecitabine)  mg/m^ SC daily x  days, or\r\n* Oral DNMTi therapy with ASTX / mg daily x  days, or\r\n* Oral DNMTi therapy with CC-  mg daily x  days
Experiences shortness of breath, chest discomfort, or palpitations when performing activities of daily living
Karnofsky >% (an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from  to  where  is \perfect\ health and  is death.)
For deep tumor cohorts, patients who require uninterrupted anticoagulants of any type, on daily aspirin therapy, or NSAIAs.
PO or IV glucocorticoid for ? wks at daily dose eq. to ?. mg of PO prednisone w/in  wks prior to study drug dosing
Breast size exceeding the technical limitation of daily set-up reproducibility. This may be center-specific and will be assessed at the discretion of the treating center.
Symptomatic neurologic disease compromising instrumental activities of daily living or requiring medication
Able to take aspirin ( or  mg) daily or for thromboprophylaxis with lenalidomide.
Daily smoker using  or more cigarettes per day
Patients/subjects who need daily oxygen therapy
Daily use of oxygen supplementation.
In good physical condition to perform low-intensity daily steps (walking)
Already doing moderate to high physical activities in their daily life (rapid screener)
Men taking propranolol on a daily for any reason are excluded
Patients/subjects who need daily oxygen therapy
Myeloma Frailty Score:\r\n*NOTE: this will include calculating a frailty score (based on age, activities of daily living, instrumental activities of daily living and Charlson comorbidity index)\r\n** Phase I: intermediate fitness or frail; NOTE: no fit patients will be included in the phase  portion of the trial which is being done to determine the MTD of the -drug combination\r\n** Phase II: transplant-ineligible as per their treating physician; NOTE: all the patients with intermediate fitness or frail status will be considered transplant-ineligible; other reasons to consider transplant ineligibility may include, but are not limited to: financial constraints or patient preference; in case such patients have a frailty score of fit, it should be duly noted by the treating physician
Demonstrated willingness and ability to record daily caloric intake either on paper or in online program
Daily caloric consumption <  calories
Subjects requiring daily corticosteroids either via oral route of administration (po) or infusion.
Clinical and microbiologic relapse of C. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment\r\n* At least  days of vancomycin at least  mg four times daily (QID), or metronidazole  mg three times daily (TID)\r\n* C. difficile associated diarrhea is defined as:\r\n** >=  loose or watery stools per day for at least  consecutive days or >=  loose stools in  hours and\r\n** Positive Clostridium difficile polymerase chain reaction (PCR)
Patients must be vulnerable or frail by Balducci Criteria or the patient is refusing breast surgery; vulnerable patients are defined as those with dependence in some instrumental activities of daily living, well controlled co-morbidities, and early symptoms of geriatric syndrome; frail patients are defined as those with three or more co-morbidities, dependence in one or more activities of daily living, or a clinically significant geriatric syndrome; geriatric syndromes include: dementia, delirium, incontinence (fecal and/or urinary), osteoporosis or spontaneous fractures, polypharmacy, visual/hearing impairment, sarcopenia and neglect or abuse
Daily use of a second form of tobacco or nicotine (e.g. e-cigarettes, cigars, chewing tobacco, snuff)
< grade  acute graft versus host disease (GVHD) at time of the first NK cell-enriched DLI; patients with treated acute GVHD must be on a stable dose of therapy (no increase in immunosuppressive therapy for the  weeks before planned NK cell-enriched DLIs); the dosage/level of immunosuppressive therapy at the time of NK-DLIs should be no greater than mg of prednisone daily or mycophenolate  mg bid daily or cyclosporine with a target level of  ng/mL or tacrolimus with a target level of  ng/ml
Chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication
Use of full-dose anticoagulant therapy; use of daily aspirin up to  mg per day is permitted
Able to take daily aspirin ( mg) for the duration of INCB treatment and  week after the last dose to reduce the risk of thrombosis (not applicable if on other anti-coagulant therapy at time of study registration)
Patient must be able to drink and eat more than % of their usual daily meals
Myelofibrosis subjects must have been treated with ruxolitinib for ?  months with a stable dose for ?  weeks (acceptable doses are  mg twice daily [BID] to  mg BID).
History of grade  or higher radiation induced pneumonitis (severe, limiting self care activities of daily living [ADL], requiring oxygen)
thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over  mg daily or dual antiplatelet therapy;
Patients must receive a myeloablative preparative regimen containing busulfan targeted to an area under the curve (AUC) of / dose for  doses combined with fludarabine  mg/M daily for  days
History of continuous daily use of PPI more than  year prior to consent
Participant has a visual condition that compromises the ability to accurately measure visual acuity or assess visual activities of daily living (vADLs).
Participants must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diary
Daily oral or intravenous corticosteroids for  days or longer within one week of enrollment and patient is anticipated to have an increase in dose after study enrollment
No or minimal disease-related symptoms not affecting patient daily activities.
Current or recent (within  days prior to the first study drug dose) chronic daily treatment with aspirin (>  mg/day)
Low dose aspirin (?  mg daily).
For phase I, prior intolerance to imatinib at a dose of  mg daily
Participants receiving daily treatment with aspirin >mg/day or other known inhibitors of platelet function.
Subjects must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diary
The subject must be willing to apply the medications twice daily for  month
Systemic anticoagulation or daily aspirin dose exceeding  mg per day
Dose adjustment of ruxolitinib to <  mg twice daily at start of or during ruxolitinib treatment AND at least one of the following while on ruxolitinib treatment:
Patients with pulmonary disease limiting daily function or requiring oxygen supplementation
Subjects requiring therapeutic doses of anticoagulation or anti-platelet therapies (aspirin above  mg daily, Plavix or similar agents) AND platelet counts are below , on two different laboratory evaluations, separated by minimum of two weeks
Normal functioning of daily living activities
Must be able to take concurrent aspirin mg to  mg daily (or enoxaparin if aspirin allergic)
Patients with any history of hyperglycemia (elevated blood glucose level on blood chemistries) should be considered for initiation of Metformin treatment (mg, PO, twice daily) prior to starting BKM
Concurrent use of aspirin >  mg daily
Normal functioning of daily living activities
Prior daily use of tadalafil or other long-acting phosphodiesterase- (PDE) inhibitors for one month or greater
Use of - mg daily aspirin or up to  mg aspirin not more than once a week are eligible.
Regular use of aspirin in excess of  mg per week.
For patients with MPN: On ruxolitinib for at least three months and on a stable dose for at least  month prior to enrollment and taking at least  mg twice daily of ruxolitinib
Untreated T- and N- disease will be treated with radiation therapy using  to  weeks of daily radiotherapy per standard practice; must be able to anticipate meeting lung dosimetry guidelines
Able to take aspirin  mg daily
The participant is able to carry out daily life activities without difficulty
Patients must be considered ineligible for rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) standard therapy; to be ineligible for R-CHOP, patients must meet at least one of the following criteria are met:\r\n* Prior anthracycline therapy for other malignancies or other disorders whereby if additional anthracyclines are given for DLBCL, the maximum lifetime allowable dose will be exceeded\r\n* Meeting the geriatric criteria of ineligibility for standard R-CHOP if one of the following criteria is present:\r\n** Three or more organ systems with a score of  or any  organ system with a score of  (using the Cumulative Illness Rating Scale for Geriatrics, [CIRS-G])\r\n** Score of  or above on the Vulnerable Elders Survey (VES-)\r\n** Score of =<  in the short physical performance battery (SPPB)\r\n** Presence of a significant geriatric syndrome (dementia, delirium, falls, incontinence, malnutrition, and severe osteoporosis) in the past year prior to diagnosis\r\n** Any abnormality in performing activities of daily living (ADLs) or instrumental activities of daily living (IADLs)
Use of daily and/or chronic oral or ocular steroids. Individuals must be off daily steroids for at least  weeks prior to enrolling into the trial
have blast counts that can be controlled by the use of hydroxycarbamide ( to  mg daily).
Minimal immunosuppression (defined as monotherapy with =<  mg prednisone daily, =<  mg cyclosporine daily, or =<  mg tacrolimus daily) at least  weeks prior to scheduled treatment
Use of aspirin is NOT an exclusion criterion as long as the daily dose does not exceed  mg daily; initiation of ADAPT therapy requires patient to discontinue aspirin for  months
Willing to administer daily subcutaneous injections at home
Individuals on a stable ruxolitinib dose of  mg once daily
Chronic daily treatment with NSAID (occasional use for the symptomatic relief of medical conditions, for example headache or fever is allowed)
Most recent enzalutamide dose received is  mg once daily with no change in dose for at least  weeks prior to Screening.
Patients who have demonstrated intolerance to dasatinib  mg daily will not be eligible for Part III/Arm B or C of the study.
Daily smoker for ? months
Non or minimally daily activities-interfering disease related symptoms.
Must be able to take concurrent aspirin  mg daily
Willingness to take everolimus orally, once daily at the same time every day either consistently with food or consistently without food
Patients with multifocal peripheral sensory alterations or paresthesias (including tingling) interfering with function, per patient report (example: activities of daily living)
Receiving chronic daily treatment with aspirin (>  mg/day) or other known inhibitors of platelet function
Requirement for immediate or urgent treatment with daily vemurafenib and for whom the intermittent schedule of vemurafenib employed during the -day period for this trial is not clinically acceptable
Have chronic nausea that has been present for at least one week (worst daily score > , - visual analogue scale) or vomiting at least five times over past one week
Must be able to perform basic activities of daily living (as determined by referring study recruiter at intake)
Consistent daily access to a smartphone
Able to perform basic activities of daily living (ADLs)
History of chronic narcotic use, defined as  days or more of preoperative daily narcotic use, measured from the date of surgery
Subjects who have been drinking >  alcoholic drinks daily for the last year
Pre-existing pain in the axilla affecting ability to use extremity for activities of daily living or requiring medication for treatment
Patients taking more than  mg of Aspirin daily
Experiences shortness of breath, chest discomfort, or palpitations when performing activities of daily living
Current daily smoker
Presence of active malabsorption disorder (e.g., flare episodes documented within the preceding  months, presence of symptoms requiring daily medications for control) or history of extensive small bowel resection
Able and willing to document symptoms and treatment details as often as needed, not to exceed daily notes
Patients must currently be taking one of the following aromatase inhibitor (AI) doses for at least  days prior to registration and plans to continue for at least an additional  days after registration; patients may have received any number of prior AI therapies, but the first AI therapy must have started no more than  months prior to registration:\r\n* Anastrozole (Arimidex)  mg daily\r\n* Letrozole (Femara) . mg daily\r\n* Exemestane (Aromasin)  mg daily
Women who are currently on omega- fatty acid supplements with >  mg of eicosapentaenoic acid (EPA) + DHA daily or  mg of DHA alone and or who have chronically been on more than  fish oil capsule per day; there is no exclusion based on fish intake
Functional limitations requiring a walker/scooter/wheelchair for daily activities
Chronic narcotic use (daily or near daily use for >  days)
Concomitant immunosuppressive medications, such as methotrexate or TNF inhibitors, within  weeks of Study Day , exclusive of steroid doses ?  mg daily.
Patients taking concomitant diuretics or dihydropyridine class of calcium channel blockers must be on a stable daily dose for at least  months prior to enrollment
Taking vismodegib daily at time of enrollment
Patient is willing to take finasteride  mg orally daily for -month treatment period
Current daily use of aspirin (>  mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within  days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen >  mg daily or equivalent)
Reports being unwilling to use Continuous Glucose Monitor (CGM), which requires daily blood sampling by finger pricks.
SOCIAL MEDIA STUDY: Daily use of Facebook
Smoke at least  cigarettes daily for the past year
Have used smokeless tobacco for the last year, currently (past  days) uses smokeless tobacco daily, and chews/dips at least  times a day
Agree to follow a berry-free/controlled polyphenol diet and to document consumption of polyphenolic foods each day of the study using a simple daily form
Current or anticipated need for daily aspirin or NSAID use including aspirin for cardiovascular protection
Daily therapy with H blockers or protein pump inhibitors
Daily use of Facebook
Smoke at least  cigarettes daily for the past year
Smoked daily for the past one year
Subject has been receiving ruxolitinib therapy for intermediate or high-risk myelofibrosis for > months prior to enrollment with no more than  dose reduction of ruxolitinib in the - weeks prior to enrollment and a stable daily dose ? mg twice daily (BID) > months prior to enrollment.
Daily DHA consumption =<  mg/day in the month prior to screening estimated by an abbreviated DHA food frequency questionnaire
Daily treatment with thiazides or ?-blockers (exclusion only if <  months)
Subjects will receive the standard Food and Drug Administration (FDA)-approved dose and schedule of -azacytidine; this dose is  mg/m^ SC or intravenously (IV) daily for seven days with cycles repeated every  days
Routine daily use of duloxetine and/or milnacipran
Smoke at least five cigarettes daily for the past year
Aim  only: Smokeless tobacco users who use ST daily (>=  dips or pouches/day) for at least  months and no other tobacco use or e-cig use for at least  year (ST use will be confirmed by salivary cotinine), and in good physical and mental health; no serious quit attempts in the last three months particularly for those randomized to the control condition
No daily NSAIDs intake within the past  weeks; intermittent non-daily NSAIDs is allowed under principle investigator (PI) discretion
Daily smoker;
Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of -